Detalhe da pesquisa
1.
Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease.
Cell
; 167(3): 843-857.e14, 2016 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-27720451
2.
GLP-1-directed NMDA receptor antagonism for obesity treatment.
Nature
; 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38750368
3.
100 years of glucagon and 100 more.
Diabetologia
; 66(8): 1378-1394, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37367959
4.
GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease.
Cardiovasc Diabetol
; 22(1): 217, 2023 08 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37592302
5.
Plasma proteome profiles treatment efficacy of incretin dual agonism in diet-induced obese female and male mice.
Diabetes Obes Metab
; 23(1): 195-207, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33001570
6.
Sirtuin 1 and sirtuin 3: physiological modulators of metabolism.
Physiol Rev
; 92(3): 1479-514, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22811431
7.
Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety.
Molecules
; 24(10)2019 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31091786
8.
Current and Emerging Treatment Options in Diabetes Care.
Handb Exp Pharmacol
; 233: 437-59, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-25903416
9.
GLP-1-oestrogen attenuates hyperphagia and protects from beta cell failure in diabetes-prone New Zealand obese (NZO) mice.
Diabetologia
; 58(3): 604-14, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25527001
10.
The GLP-1R as a model for understanding and exploiting biased agonism in next-generation medicines.
J Endocrinol
; 261(2)2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38451873
11.
Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice.
Mol Metab
; 83: 101915, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38492844
12.
Optimization of peptide-based polyagonists for treatment of diabetes and obesity.
Bioorg Med Chem
; 26(10): 2873-2881, 2018 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29153547
13.
GIPR/GLP-1R dual agonist therapies for diabetes and weight loss-chemistry, physiology, and clinical applications.
Cell Metab
; 35(9): 1519-1529, 2023 09 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37591245
14.
The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets.
Nat Metab
; 5(6): 945-954, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37277609
15.
Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice.
Nat Metab
; 5(12): 2075-2085, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37946085
16.
GLP-1/GIP/glucagon receptor triagonism gets its try in humans.
Cell Metab
; 34(1): 3-4, 2022 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34986336
17.
Hepatic mTORC2 Signaling Facilitates Acute Glucagon Receptor Enhancement of Insulin-Stimulated Glucose Homeostasis in Mice.
Diabetes
; 71(10): 2123-2135, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35877180
18.
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice.
Mol Metab
; 63: 101533, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35809773
19.
Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems.
Mol Metab
; 66: 101638, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36400403
20.
Vps37a regulates hepatic glucose production by controlling glucagon receptor localization to endosomes.
Cell Metab
; 34(11): 1824-1842.e9, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36243006